Navigation Links
Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
Date:11/20/2007

MARKHAM, ON, Nov. 20 /PRNewswire/ - Cytochroma Inc. announced today that it has commenced dosing in a Phase I/II clinical trial of CTAP101 Capsules, the Company's product candidate for the treatment of vitamin D insufficiency in chronic kidney disease (CKD).

This Phase I/II clinical trial is a four-week, open label trial designed to establish the pharmacokinetic profile and safety of CTAP101 Capsules in subjects with vitamin D insufficiency. The product's pharmacokinetic profile will be characterized at low-, mid- and high-dosages in subjects with normal renal function, and at a single mid-dosage in subjects with Stage 3 and 4 CKD. The safety endpoints for the trial include serum and urine calcium, serum phosphorus and the serum calcium times serum phosphorus product.

"We are pleased to be advancing this first-in-class prohormone therapy into the clinic," stated Dr. Joel Melnick, Vice President, Clinical & Regulatory Affairs. "CTAP101 Capsules are designed specifically to address the marginal effectiveness of high-dose ergocalciferol (vitamin D(2)) in treating vitamin D insufficiency in CKD while providing a safer alternative to current off-label use of vitamin D hormone replacement therapies."

About CTAP101 Capsules

CTAP101 Capsules are a first-in-class treatment for vitamin D insufficiency in CKD patients. CTAP101 Capsules are designed to reliably boost circulating vitamin D prohormone levels to above the minimum adequate level established by the National Kidney Foundation (NKF) in its Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines. CTAP101 Capsules can potentially help nephrologists treat and/or prevent secondary hyperparathyroidism which develops in most CKD patients in part because of vitamin D insufficiency.

About Chronic Kidney Disease and Vitamin D Insufficiency

According to the NKF, more than nine million North American patients suffer from moderate CKD (Stage 3 and 4) to severe CKD (Stage 5). An es
'/>"/>

SOURCE Cytochroma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... JUPITER, Fla. , Aug. 18, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... and other proteins for the bioenergy, bio-based chemical, ... it has filed a Registration Statement on Form ... (the "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... heat during the production of electricity could be ... via a technique developed by researchers with the ... Laboratory (Berkeley Lab) and the University of California ... this technology include DOEs hydrogen fuel cell-powered Freedom ...
... in the Philadelphia suburbs, with unique new capabilities enabled by Masimo ... ... technologies, IRVINE, Calif., Jan. 10 Abington Memorial,Hospital and ... & Low Perfusion Pulse Oximetry, have announced the,completion of Philadelphia-based Abington ...
... Ky., Lexington, Ky., and Newport News, Va. Also ... ... spirit of excellence and remarkable achievements in its,community, Harborview Medical Center of ... is one of the most esteemed,honors of excellence in community service in ...
Cached Biology Technology:Feeling the heat 2Feeling the heat 3Feeling the heat 4Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6
(Date:8/18/2014)... Half of the Earth,s land mass is made ... they are being transformed at an alarming rate. Woody ... and taking over, leading to a loss of critical ... of ecosystems to produce food specifically meat. ... Sciences led an investigation that quantified this loss in ...
(Date:8/18/2014)... Researchers from Aarhus University, Denmark, and the University of Wisconsin-Madison, ... exposure of species to both climate and land use change. ... species in the face of combined rates of climate and ... , Their results, which have just been published in ... vulnerable to losses in biodiversity and ecosystem function due to ...
(Date:8/18/2014)... the pygmy phenotype is probably a selective adaptation ... of researchers, but all African pygmy phenotypes do ... more recent adaptation than previously thought., "I,m interested ... very challenging environments," said George H. Perry, assistant ... rainforests are difficult for humans to live in. ...
Breaking Biology News(10 mins):Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3The double threat of climate and land use change enhances risks to biodiversity 2Pygmy phenotype developed many times, adaptive to rainforest 2
... 28, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a ... drugs to treat diseases of aging, announced today that ... developed novel drug candidates that offer a promising, new ... Diabetes, by targeting SIRT1, a gene that controls the ...
... Although a high standard of morality gives but a ... his children over the other men of the same ... give an immense advantage to one tribe over another. ... an evolutionary explanation for morality and pro-social behaviors individuals ...
... able to form abstract concepts. Friederike Range and ... shown for the first time that dogs can classify ... the same way that humans do. And the ... computer automated touch-screens, eliminating potential human influence. The ...
Cached Biology News:Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 2Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 3Group selection, a theory whose time has come...again 2Computer savvy canines 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: